News & Media

Read about our latest news and initiatives, and find more information about Acadia.

News Releases

December 19, 2024
General

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

December 16, 2024
General

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2024
General

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

View All

Featured Perspectives

A mother embraces her young daughter in a bedroom, both sharing a tender moment

November 13, 2024
Acadia Story

Celebrating Caregivers

Group of young professionals gathered outdoors, smiling together during a company event, reflecting teamwork and engagement

September 5, 2024
Acadia Story

A Summer of Growth: My Internship at Acadia

Hero image celebrating moms’ resilience, featuring a symbolic illustration of strength and unity, set against a warm, inspirational background

May 11, 2023
Acadia Story

Celebrating Moms: Inspiring Stories of Strength and Resilience

View All

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.

About Acadia